文献速递肝病消化道肿瘤与早癌

脂肪性肝病通过诱导YAP/TAZ驱动的细胞竞争抑制肿瘤起始

Steatotic liver disease induces YAP/TAZ-driven cell competition that can suppress tumor initiation.
PubMed 文献 · J Hepatol · 2025-06-06

该研究在小鼠模型中探讨单纯性脂肪变(无显著纤维化和炎症)对肝癌发生的影响。西方饮食诱导早期MASLD可激活脂肪变性肝细胞中的Yap/Taz并增强其竞争性,从而清除肿瘤起始细胞、抑制肿瘤发生;进展为晚期MASH后该抑瘤效应消失。

要点

  • 早期MASLD通过Yap/Taz介导的细胞竞争抑制小鼠肝癌起始。
  • 该抑瘤效应源于周围肝细胞竞争力增强,而非直接作用于致癌基因表达细胞。
  • 进展为晚期MASH后,炎症和纤维化削弱非突变肝细胞竞争力,抑瘤效应丧失。

核心结论

  • 早期MASLD中的脂肪变性肝细胞激活Yap/Taz依赖性细胞竞争程序,可抑制肿瘤起始。
  • 该抑瘤效应在晚期MASH中丧失,炎症、纤维化等缺陷削弱非突变肝细胞的竞争力。

研究设计与样本

  • 研究为小鼠模型实验,通过西方饮食诱导早期MASLD(脂肪变伴轻度肝炎、无纤维化),并用水动力尾静脉注射编码致癌基因的质粒触发肝肿瘤发生。
  • 结合Hippo信号通路的遗传操作,采用组织学和单核RNA测序评估肿瘤发展。

主要发现

  • 西方饮食通过促进肿瘤起始细胞的清除来抑制肝肿瘤发展。
  • 该效应并非直接作用于致癌基因表达细胞,而是源于周围肝细胞竞争力增强。
  • 西方饮食激活脂肪变性肝细胞中的Hippo通路效应因子Yap和Taz,使其能够竞争胜过肿瘤起始细胞。
  • 进展为晚期MASH后,该肿瘤抑制效应消失,允许肿瘤发展。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Metabolic dysfunction-associated steatotic liver disease (MASLD) and its advanced form, metabolic dysfunction-associated steatohepatitis (MASH), are leading risk factors for liver cancer. While inflammation and fibrosis are known to promote tumorigenesis in MASH, the role of early MASLD in cancer initiation is unclear. Here, we investigated how steatosis alone, without significant fibrosis and inflammation, influences liver cancer development in mouse models. METHODS: We fed mice a Western diet to induce early-stage MASLD, characterized by steatosis and mild hepatitis without fibrosis, and triggered liver tumorigenesis by hydrodynamic tail vein injection of plasmids encoding oncogenes. We combined this with genetic manipulation of Hippo signaling and assessed tumor development using histology and single-nucleus RNA sequencing. RESULTS: Western diet suppressed liver tumor development by promoting the elimination of tumor-initiating cells. This effect was not due to a direct impact on oncogene-expressing cells, but rather to increased competitiveness of the surrounding hepatocytes. Mechanistically, the Western diet activated the Hippo pathway effectors Yap and Taz in steatotic hepatocytes, enabling them to outcompete tumor-initiating cells. Progression to advanced MASH abrogated this tumor-suppressing effect, allowing tumor development. CONCLUSIONS: Steatotic hepatocytes in early MASLD activate a Yap/Taz-dependent cell competition program that can suppress tumor initiation. This tumor-suppressive effect is lost in advanced MASH, where inflammation, fibrosis and other defects undermine the competitiveness of non-mutant hepatocytes. The tumor-suppressive effect of early MASLD adds a new layer to our understanding of how fitness landscapes and cell interactions shape cancer risk during chronic liver disease. IMPACT AND IMPLICATIONS: We found that early stages of steatotic liver disease (MASLD) can suppress tumor initiation in mouse models of liver cancer by triggering Yap/Taz-mediated cell competition. This reveals an unexpected tumor-suppressive role for early MASLD and highlights the importance of non-cell autonomous mechanisms during tumor initiation. Since Hippo-YAP/TAZ signaling is deregulated in many cancers, similar mechanisms may operate in other tissues.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Algueró-Nadal A, Mol H, Zoppolato E, et al. Steatotic liver disease induces YAP/TAZ-driven cell competition that can suppress tumor initiation. J Hepatol. 2025. PMID: 40484249. doi:10.1016/j.jhep.2025.06.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。